Products & Research
Product Pipeline
Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.
Acorda’s R&D efforts are designed to:
- Develop CVT-301 and tozadenant as potential therapies for Parkinson’s disease
- Advance CVT-427 as a potential acute treatment for migraine
- Determine if SYN120 is a therapeutic option for people with Parkinson’s disease dementia
- Advance clinical development of rHIgM22, a remyelinating antibody, as a potential treatment for people with MS
Click on a compound in development for more information.
| Therapy | THERAPEUTIC AREA | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
CVT-301 |
Parkinson's Disease |
|||
TOZADENANT |
Parkinson's Disease |
|||
SYN120 |
Parkinson's Disease |
|||
BTT1023 (timolumab) |
Primary Sclerosing Cholangitis (PSC) |
|||
CVT-427 |
Migraine |
|||
rHlgM22 |
MS |
